Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Izokibep - Affibody

Drug Profile

Izokibep - Affibody

Alternative Names: ABY 035; ABY-035/AFO2; AFB-035; IMG-020; IMG-20

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affibody
  • Developer ACELYRIN; Affibody; Inmagene
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hidradenitis suppurativa
  • Phase II/III Psoriatic arthritis; Uveitis
  • Phase II Ankylosing spondylitis; Axial spondyloarthritis; Plaque psoriasis
  • Phase I/II Psoriasis
  • Phase I Unspecified

Most Recent Events

  • 11 Mar 2024 Efficacy and adverse events data from a phase-IIb/III trial in Psoriatic arthritis released by ACELYRIN
  • 21 Feb 2024 ACELYRIN completed a phase II/III trial in Hidradenitis suppurativa in USA, Spain, Poland, Hungary, Germany, Canada (SC) (NCT05355805)
  • 10 Nov 2023 Updated efficacy and adverse event data from a phase II trial in Psoriatic arthritis presented at the ACR Convergence 2023 (ACR-ARP-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top